Cellular Cancer Markers

✍ Scribed by Stewart Sell, Carleton T. Garrett (auth.), Carleton T. Garrett MD, PhD, Stewart Sell MD (eds.)

• Publisher: Humana Press
• Year: 1995
• Tongue: English
• Leaves: 490
• Series: Contemporary Biomedicine 12
• Edition: 1
• Category: Library

✦ Synopsis

In Cellular Cancer Markers leading pathologists and physicians review today's most promising cellular cancer markers, an important emerging class of prognostic markers that can be used in the clinical evaluation of cancer patients. The markers reviewed have been chosen because they are biologically relevant to the growth of cells and possess an accurate and reproducible assay for detection. They also are predictors of tumor behavior, are useful in making clinical decisions, and are cost effective.

Cellular Cancer Markers provides a status report for markers of tumor cell activation, proliferation, and longevity that makes possible an informed judgment regarding the value of many newly proposed tumor markers. It also offers insight into the latest approaches to diagnosing cancer and an appreciation of how these marker-based tests can clarify the prognosis of cancer.

✦ Table of Contents

Front Matter....Pages i-xi
Clinical Application of Genetic, Oncogenic, and Differentiation Markers of Cancer....Pages 1-16
ras Proto-Oncogene Activation in Human Malignancy....Pages 17-52
C- myc as a Tumor Marker for Primary Human Cancers....Pages 53-76
p53 in Human Cancer....Pages 77-110
Oncogenes and Tumor-Suppressor Genes in Gynecological Malignancies....Pages 111-138
Genetic Alterations in Colon Cancer....Pages 139-189
Genetic Changes in Breast Cancer....Pages 191-208
Genetic Alterations in Lung Cancer....Pages 209-229
Wilms Tumor-Susceptibility Loci....Pages 231-255
Non-Hodgkin’s Lymphomas....Pages 257-288
Phenotypic Expression of Hodgkin’s Disease....Pages 289-334
Melanoma Markers....Pages 335-350
Detection of Minimal Residual Disease (MRD) in Leukemia and Lymphoma....Pages 351-374
P-Glycoproteins in Tumors....Pages 375-391
Genetically Engineered Antitumor Monoclonal Antibodies....Pages 393-432
Targeting Antisense Oligonucleotide Chemotherapy to the Type I Regulatory Subunit of cAMP-Dependent Protein Kinase....Pages 433-454
Summary and Perspective....Pages 455-477
Back Matter....Pages 479-484

✦ Subjects

Pathology